Información del artículo
Resumen
El pasado mes de marzo se publicaron, en el mismo número de la revista New England Journal of Medicine, 3 estudios que evaluaban la eficacia del tratamiento endovascular en el ictus isquémico. El resultado ha sido una fuerte controversia entre neurólogos y neurorradiólogos intervencionistas. Sus resultados negativos han levantado numerosas críticas que han señalado graves deficiencias metodológicas. En este trabajo analizamos la evolución de la terapia trombolítica en el ictus, así como las debilidades y fortalezas de dichos estudios. A pesar de sus resultados negativos, pueden marcar la dirección correcta de nuevos ensayos que justifiquen esta modalidad de tratamiento respaldada por la evidencia científica.
Palabras clave:
Ictus
Trombectomía mecánica
Stentrievers
Trombólisis
Recanalización
Abstract
Last March, in a single issue New England Journal of Medicine published 3 studies that evaluated the efficacy of endovascular treatment for ischemic stroke, leading to a heated controversy between neurologists and interventional neuroradiologists. The negative results have resulted in numerous reviews pointing out serious methodological defects. In this article, we analyze the outcomes of thrombolytic treatment for stroke and discuss the strengths and weaknesses of the three above-mentioned studies. Despite the negative results, these studies can point the way for new trials that will justify this treatment modality that is backed up by scientific evidence.
Keywords:
Stroke
Mechanical thrombectomy
Stentrievers
Thrombolysis
Recanalization
Artículo
Opciones para acceder a los textos completos de la publicación Radiología
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
J.P. Broderick, Y.Y. Palesch, A.M. Demchuk, S.D. Yeatts, P. Khatri, M.D. Hill, et al.
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.
N Engl J Med, 368 (2013), pp. 893-903
[2]
A. Ciccone, L. Valvassori, M. Nichelatti, A. Sgoifo, M. Ponzio, R. Sterzi, et al.
Endovascular treatment for acute ischemic stroke.
N Engl J Med, 368 (2013), pp. 904-913
[3]
C.S. Kidwell, R. Jahan, J. Gornbein, J.R. Alger, V. Nenov, Z. Ajani, et al.
A trial of imaging selection and endovascular treatment for ischemic stroke.
N Engl J Med, 368 (2013), pp. 914-923
[4]
Endovascular procedures no better than medical care for acute stroke. BMJ. 2013;346:877.
[5]
M.I. Chimowitz.
Endovascular treatment for acute ischemic stroke–still unproven.
N Engl J Med, 368 (2013), pp. 952-955
[6]
M. Arnold, G. Schroth, J. Gralla.
Endovascular treatment for acute ischemic stroke.
N Engl J Med, 368 (2013), pp. 2431
[7]
J.E. Cohen, R.R. Leker.
Endovascular treatment for acute ischemic stroke.
N Engl J Med, 368 (2013), pp. 2432
[8]
B.C. Campbell, G.A. Donnan, S.M. Davis.
Endovascular treatment for acute ischemic stroke.
N Engl J Med, 368 (2013), pp. 2431-2432
[9]
M. Goyal.
Acute stroke trials: the elephant in the room.
Neuroradiology, 55 (2013), pp. 929-931
[10]
S. Calleja-Puerta, J. Vega-Villar.
Time is still brain: the ball is in the court of neurovascular interventionist treatment.
Rev Neurol, 56 (2013), pp. 305-308
[11]
M. Kaijser, T. Andersson.
Endovascular treatment for acute ischemic stroke.
N Engl J Med, 368 (2013), pp. 2430
[12]
C. Gakuba, M. Gauberti, D. Vivien.
Endovascular treatment for acute ischemic stroke.
N Engl J Med, 368 (2013), pp. 2430-2431
[13]
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Tissue plasminogen activator for acute ischemic stroke.
N Engl J Med, 333 (1995), pp. 1581-1587
[14]
W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Dávalos, D. Guidetti, et al.
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
N Engl J Med, 359 (2008), pp. 1317-1329
[15]
J.H. Rha, J.L. Saver.
The impact of recanalization on ischemic stroke outcome: A meta-analysis.
Stroke, 38 (2007), pp. 967-973
[16]
J.L. Saver.
Time is brain–quantified.
Stroke, 37 (2006), pp. 263-266
[17]
K.R. Lees, E. Bluhmki, R. von Kummer, T.G. Brott, D. Toni, J.C. Grotta, et al.
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
Lancet, 375 (2010), pp. 1695-1703
[18]
A. Furlan, R. Higashida, L. Wechsler, M. Gent, H. Rowley, C. Kase, et al.
Intra-arterial prourokinase for acute ischemic stroke — the PROACT II study: a randomized controlled trial.
JAMA, 282 (1999), pp. 2003-2011
[19]
W.S. Smith, G. Sung, J. Saver, R. Budzik, G. Duckwiler, D.S. Liebeskind, et al.
Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial.
Stroke, 39 (2008), pp. 1205-1212
[20]
Penumbra Pivotal Stroke Trial Investigators.
The Penumbra Pivotal Stroke Trial: Safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease.
Stroke, 40 (2009), pp. 2761-2768
[21]
C. Castaño, L. Dorado, C. Guerrero, M. Millán, M. Gomis, N. Perez de la Ossa, et al.
Mechanical thrombectomy with the Solitaire AB device in large artery occlusions of the anterior circulation: A pilot study.
Stroke, 41 (2010), pp. 1836-1840
[22]
R.L. Novakovic, G. Toth, S. Narayanan, O.O. Zaidat.
Retrievable stents, stentrievers, for endovascular acute ischemic stroke therapy.
Neurology, 79 (2012), pp. S148-S157
[23]
J.L. Saver, R. Jahan, E.I. Levy, T.G. Jovin, B. Baxter, R.G. Nogueira, et al.
Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial.
Lancet, 380 (2012), pp. 1241-1249
[24]
R.G. Nogueira, H.L. Lutsep, R. Gupta, T.G. Jovin, G.W. Albers, G.A. Walker, et al.
Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial.
Lancet, 380 (2012), pp. 1231-1240
[25]
E.C. Jauch, J.L. Saver, H.P. Adams Jr., A. Bruno, J.J. Connors, B.M. Demaerschalk, et al.
Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke, 44 (2013), pp. 870-947
[26]
Demchuk A. IMS III. Comparison of Outcomes between IV and IV/IA Treatment in Baseline CTA Confirmed ICA, M1, M2 and Basilar Occlusions. Honolulu: Conferencia Internacional de Ictus; 2013.
[27]
G.W. Albers, V.N. Thijs, L. Wechsler, S. Kemp, G. Schlaug, E. Skalabrin, et al.
Magnetic resonance imaging profiles predict clinical response to early reperfusion: The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study.
Ann Neurol, 60 (2006), pp. 508-517
[28]
S.M. Davis, G.A. Donnan, M.W. Parsons, C. Levi, K.S. Butcher, A. Peeters, et al.
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
Lancet Neurol, 7 (2008), pp. 299-309
[29]
M.G. Lansberg, M. Straka, S. Kemp, M. Mlynash, L.R. Wechsler, T.G. Jovin, et al.
MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study.
Lancet Neurol, 11 (2012), pp. 860-867
